Innovation Zed has partnered with GluCare.Health, a leading metabolic disease management platform, to provide connected insulin pen technology as part of a combination product in GluCare.Health's digital clinic ecosystem.
Dubai, United Arab Emirates: Innovation Zed, an Irish R&D company specialized in the design, development, and manufacturing of innovative medical devices and the creator of novel add-on technologies for drug delivery and enhanced therapy (the InsulCheck range), has partnered with GluCare.Health, a leading metabolic disease management platform, to provide connected insulin pen technology as part of a combination product in GluCare.Health's digital clinic ecosystem. The partnership aims to support various drug delivery devices and injection pens for multiple drug therapies, collecting valuable data such as the timestamp of injection events, dosage, temperature, and user behavior to personalize therapy and improve treatment compliance.
The InsulCheck technologies available under the InsulCheck brand are smart add-on devices that can be connected to an app to auto log and store vital information and data regarding injection history for MDI (Multiple Daily Injection) users. By integrating these technologies, GluCare.Health can better manage its insulin-dependent patients continuously, as it now receives real-time information on insulin doses and timings. This enables the company to monitor insulin information with glucose and other data parameters, providing a more comprehensive picture of patients' health status and needs.
Dr. Dean Minnock, CEO at Innovation Zed, expressed his excitement about the partnership, saying, “Having developed our technologies with the initial focus of insulin therapy for diabetes, we have created a product that we have long believed would be extremely beneficial to any person requiring multiple daily injections. This opportunity from GluCare.Health to adapt and apply our InsulCheck technologies to new injection pens allows us to support therapy requirements and will see Innovation Zed now leap into new markets and most importantly support new audiences.”
The partnership is also expected to improve adherence to injection therapy, one of the most challenging aspects of any MDI therapy. By motivating people to increase adherence to their daily injection schedule, this collaboration has the potential to improve therapy response and overall outcomes.
Dr. Ihsan Almarzooqi, Co-Founder and Managing Director of GluCare.Health, said, “GluCare Health’s model of continuous care has shown to be vastly better than the episodic care practiced by traditional care providers. This partnership is a significant step forward for GluCare.Health in our mission to close the loop for insulin-dependent diabetics and obtain new data points previously blind to healthcare providers such as insulin timing, doses and temperature. Along with our engagement and meta[bolic] scores, we will be able to further personalize treatment and manage compliance under our clinic-in-the cloud model for multi dose insulin (MDI) patients.”
The partnership between Innovation Zed and GluCare.Health represents a significant milestone in the management of diabetes, and both companies look forward to the positive impact this collaboration will have on the lives of people living with diabetes.
For further information contact:
Zeina Abdalla,
Andrew Fitzpatrick,
Innovation Zed